Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CYTK Stock Forecast

Cytokinetics stock forecast is as follows: an average price target of $83.23 (represents a 66.93% upside from CYTK’s last price of $49.86) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

CYTK Price Target

The average price target for Cytokinetics (CYTK) is $83.23 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $45.00. This represents a potential 66.93% upside from CYTK's last price of $49.86.

CYTK Analyst Ratings

Buy

According to 13 Wall Street analysts, Cytokinetics's rating consensus is 'Buy'. The analyst rating breakdown for CYTK stock is 0 'Strong Buy' (0.00%), 11 'Buy' (84.62%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cytokinetics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 17, 2024	Joseph Pantginis	H.C. Wainwright	$120.00	$55.28	117.08%	140.67%
Sep 03, 2024	Paul Choi	Goldman Sachs	$60.00	$54.56	9.97%	20.34%
Jun 10, 2024	Yasmeen Rahimi	Piper Sandler	$107.00	$53.21	101.09%	114.60%
Jun 04, 2024	Mayank Mamtani	B.Riley Financial	$92.00	$48.70	88.91%	84.52%
May 28, 2024	Jason Butler	JMP Securities	$78.00	$48.30	61.49%	56.44%
May 23, 2024	Joseph Pantginis	H.C. Wainwright	$90.00	$48.71	84.77%	80.51%
May 23, 2024	Serge Belanger	Needham	$72.00	$59.23	21.56%	44.40%
May 23, 2024	Akash Tewari	Jefferies	$85.00	$59.23	43.51%	70.48%
May 23, 2024	Carter Gould	Barclays	$95.00	$59.23	60.39%	90.53%
May 09, 2024	Justin Kim	Oppenheimer	$106.00	$65.27	62.40%	112.60%

Row per page

Go to

The latest Cytokinetics stock forecast, released on Oct 17, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $120.00, which represents a 117.08% increase from the stock price at the time of the forecast ($55.28), and a 140.67% increase from CYTK last price ($49.86).

Cytokinetics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	12
Avg Price Target	-	$90.00	$92.50
Last Closing Price	$49.86	$49.86	$49.86
Upside/Downside	-100.00%	80.51%	85.52%

In the current month, the average price target of Cytokinetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytokinetics's last price of $49.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 17, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 20, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 03, 2024	Goldman Sachs	Neutral	Neutral	Hold
Aug 13, 2024	Goldman Sachs	-	Neutral	Downgrade
Jun 10, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 04, 2024	B. Riley	Buy	Buy	Hold
May 23, 2024	H.C. Wainwright	Buy	Buy	Hold
May 23, 2024	Needham	Buy	Buy	Hold
May 23, 2024	Jefferies	Buy	Buy	Hold
May 23, 2024	Barclays	Overweight	Overweight	Hold

Row per page

Go to

Cytokinetics's last stock rating was published by H.C. Wainwright on Oct 17, 2024. The company gave CYTK a "Buy" rating, the same as its previous rate.

Cytokinetics Financial Forecast

Cytokinetics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$378.00K	$867.00K	$4.61M	$1.96M	$2.52M	$88.97M	$1.15M	$55.60M	$5.44M	$2.84M	$6.55M	$6.72M	$41.69M	$3.59M	$3.83M	$5.21M	$6.05M
Avg Forecast	$106.50M	$68.94M	$45.96M	$30.64M	$16.73M	$3.58M	$1.75M	$508.00K	$5.24M	$1.21M	$7.61M	$912.85K	$7.62M	$20.24M	$5.67M	$2.08M	$7.10M	$3.51M	$3.73M	$4.34M	$5.80M	$5.98M	$5.52M	$6.57M	$23.76M	$4.02M	$4.07M	$5.01M	$7.20M	$7.52M
High Forecast	$383.70M	$248.40M	$165.60M	$110.40M	$60.26M	$12.90M	$6.30M	$1.83M	$18.87M	$1.25M	$7.61M	$912.92K	$39.92M	$20.24M	$20.41M	$7.51M	$25.58M	$3.51M	$3.73M	$4.34M	$5.80M	$5.98M	$5.52M	$6.57M	$23.76M	$4.02M	$4.07M	$5.01M	$7.20M	$7.52M
Low Forecast	$5.43M	$3.52M	$2.34M	$1.56M	$852.80K	$182.55K	$89.14K	$25.90K	$266.99K	$1.17M	$7.61M	$912.77K	$319.32K	$20.24M	$288.84K	$106.28K	$362.01K	$3.51M	$3.73M	$4.34M	$5.80M	$5.98M	$5.52M	$6.57M	$23.76M	$4.02M	$4.07M	$5.01M	$7.20M	$7.52M
# Analysts	1	1	1	1	1	1	1	3	11	5	5	10	11	5	5	9	5	4	4	7	5	5	10	7	9	9	9	9	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.02%	0.15%	2.21%	0.28%	0.72%	23.84%	0.26%	9.58%	0.91%	0.52%	1.00%	0.28%	10.38%	0.88%	0.76%	0.72%	0.81%

Cytokinetics's average Quarter revenue forecast for Dec 23 based on 11 analysts is $7.62M, with a low forecast of $319.32K, and a high forecast of $39.92M. CYTK's average Quarter revenue forecast represents a 1914.79% increase compared to the company's last Quarter revenue of $378.00K (Sep 23).

Cytokinetics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	11	5	5	10	11	5	5	9	5	4	4	7	5	5	10	7	9	9	9	9	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-115.43M	$-115.27M	$-118.05M	$-121.11M	$-102.89M	$-10.01M	$-77.44M	$-21.35M	$-68.51M	$-54.07M	$-39.78M	$-33.79M	$6.80M	$-30.56M	$-29.23M	$-21.98M	$-22.57M
Avg Forecast	$-106.50M	$-68.94M	$-45.96M	$-30.64M	$-16.73M	$-3.58M	$-1.75M	$-508.00K	$-5.24M	$-1.21M	$-7.61M	$-60.82M	$-7.62M	$-20.24M	$-5.67M	$-65.05M	$-33.21M	$-3.51M	$-3.73M	$-69.57M	$-5.80M	$-5.98M	$-5.52M	$-34.30M	$-23.76M	$-4.02M	$-4.07M	$-19.88M	$-7.20M	$-7.52M
High Forecast	$-5.43M	$-3.52M	$-2.34M	$-1.56M	$-852.80K	$-182.55K	$-89.14K	$-25.90K	$-266.99K	$-1.17M	$-7.61M	$-48.66M	$-319.32K	$-20.24M	$-288.84K	$-52.04M	$-26.57M	$-3.51M	$-3.73M	$-55.66M	$-5.80M	$-5.98M	$-5.52M	$-27.44M	$-23.76M	$-4.02M	$-4.07M	$-15.90M	$-7.20M	$-7.52M
Low Forecast	$-383.70M	$-248.40M	$-165.60M	$-110.40M	$-60.26M	$-12.90M	$-6.30M	$-1.83M	$-18.87M	$-1.25M	$-7.61M	$-72.99M	$-39.92M	$-20.24M	$-20.41M	$-78.06M	$-39.85M	$-3.51M	$-3.73M	$-83.49M	$-5.80M	$-5.98M	$-5.52M	$-41.16M	$-23.76M	$-4.02M	$-4.07M	$-23.85M	$-7.20M	$-7.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	5.70%	20.35%	1.81%	3.65%	29.34%	2.68%	1.11%	3.68%	11.45%	9.80%	1.16%	1.42%	-1.69%	7.50%	1.47%	3.06%	3.00%

9 analysts predict CYTK's average Quarter EBITDA for Dec 20 to be $-23.76M, with a high of $-23.76M and a low of $-23.76M. This is -449.57% lower than Cytokinetics's previous annual EBITDA (Sep 20) of $6.80M.

Cytokinetics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	11	5	5	10	11	5	5	9	5	4	4	7	5	5	10	7	9	9	9	9	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-129.42M	$-128.64M	$-129.44M	$-131.46M	$-176.18M	$-28.77M	$-101.03M	$-39.06M	$-76.09M	$-61.55M	$-47.10M	$-43.93M	$-3.17M	$-40.78M	$-39.41M	$-30.64M	$-29.57M
Avg Forecast	$-75.32M	$-103.56M	$-122.39M	$-129.45M	$-144.46M	$-157.93M	$-149.93M	$-145.93M	$-151.88M	$-145.29M	$-124.34M	$-69.04M	$-112.80M	$-87.42M	$-134.09M	$-73.84M	$-47.56M	$-127.14M	$-112.47M	$-78.98M	$-92.67M	$-84.77M	$-72.10M	$-40.61M	$-47.44M	$-36.87M	$-62.11M	$-26.80M	$-48.07M	$-53.75M
High Forecast	$17.60M	$24.20M	$28.61M	$30.26M	$33.76M	$36.91M	$35.04M	$-131.22M	$-107.48M	$33.96M	$29.06M	$-55.24M	$-55.85M	$20.43M	$31.34M	$-59.08M	$-38.05M	$-127.14M	$-112.47M	$-63.18M	$-92.67M	$-84.77M	$-72.10M	$-32.49M	$-47.44M	$-36.87M	$-62.11M	$-21.44M	$-48.07M	$-53.75M
Low Forecast	$-330.19M	$-454.01M	$-536.55M	$-567.51M	$-633.29M	$-692.36M	$-657.28M	$-166.29M	$-186.92M	$-636.94M	$-545.10M	$-82.85M	$-160.98M	$-383.24M	$-587.82M	$-88.61M	$-57.07M	$-127.14M	$-112.47M	$-94.77M	$-92.67M	$-84.77M	$-72.10M	$-48.73M	$-47.44M	$-36.87M	$-62.11M	$-32.15M	$-48.07M	$-53.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.48%	0.96%	1.75%	2.76%	1.39%	0.26%	1.28%	0.42%	0.90%	0.85%	1.16%	0.93%	0.09%	0.66%	1.47%	0.64%	0.55%

Cytokinetics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CYTK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cytokinetics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	11	5	5	10	11	5	5	9	5	4	4	7	5	5	10	7	9	9	9	9	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$40.11M	$39.72M	$49.66M	$53.97M	$48.22M	$42.72M	$33.07M	$33.81M	$26.20M	$21.20M	$15.60M	$13.91M	$12.30M	$14.16M	$12.45M	$10.58M	$9.75M
Avg Forecast	$611.97M	$396.18M	$264.12M	$176.08M	$96.12M	$20.58M	$10.05M	$2.92M	$30.09M	$6.98M	$43.71M	$5.25M	$43.76M	$116.32M	$32.55M	$11.98M	$40.80M	$20.15M	$21.44M	$24.97M	$33.34M	$34.39M	$31.71M	$37.77M	$136.56M	$23.08M	$23.40M	$28.77M	$41.35M	$43.21M
High Forecast	$2.20B	$1.43B	$951.62M	$634.41M	$346.31M	$74.13M	$36.20M	$10.52M	$108.42M	$7.20M	$43.71M	$5.25M	$229.38M	$116.32M	$117.29M	$43.16M	$147.01M	$20.15M	$21.44M	$24.97M	$33.34M	$34.39M	$31.71M	$37.77M	$136.56M	$23.08M	$23.40M	$28.77M	$41.35M	$43.21M
Low Forecast	$31.20M	$20.20M	$13.47M	$8.98M	$4.90M	$1.05M	$512.21K	$148.83K	$1.53M	$6.75M	$43.71M	$5.25M	$1.84M	$116.32M	$1.66M	$610.72K	$2.08M	$20.15M	$21.44M	$24.97M	$33.34M	$34.39M	$31.71M	$37.77M	$136.56M	$23.08M	$23.40M	$28.77M	$41.35M	$43.21M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.34%	1.22%	4.15%	1.32%	2.39%	1.99%	1.32%	1.01%	0.76%	0.67%	0.41%	0.10%	0.53%	0.61%	0.43%	0.26%	0.23%

Cytokinetics's average Quarter SG&A projection for Dec 23 is $43.76M, based on 11 Wall Street analysts, with a range of $1.84M to $229.38M. The forecast indicates a 9.11% rise compared to CYTK last annual SG&A of $40.11M (Sep 23).

Cytokinetics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	11	5	5	10	11	5	5	9	5	4	4	7	5	5	10	7	9	9	9	9	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.35	$-1.34	$-1.36	$-1.39	$-1.88	$-0.34	$-1.19	$-0.46	$-0.95	$-0.86	$-0.66	$-0.62	$-0.05	$-0.68	$-0.66	$-0.52	$-0.50
Avg Forecast	$-0.64	$-0.88	$-1.04	$-1.10	$-1.23	$-1.34	$-1.27	$-1.24	$-1.29	$-1.23	$-1.06	$-1.14	$-0.96	$-0.74	$-1.14	$-1.20	$-1.21	$-1.16	$-1.03	$-0.94	$-0.85	$-0.78	$-0.66	$-0.58	$-0.43	$-0.34	$-0.57	$-0.50	$-0.44	$-0.49
High Forecast	$0.15	$0.21	$0.24	$0.26	$0.29	$0.31	$0.30	$-1.12	$-0.91	$0.29	$0.25	$0.27	$-0.47	$0.17	$0.27	$0.28	$0.28	$-1.16	$-1.03	$-0.94	$-0.85	$-0.78	$-0.66	$-0.58	$-0.43	$-0.34	$-0.57	$-0.50	$-0.44	$-0.49
Low Forecast	$-2.81	$-3.86	$-4.56	$-4.82	$-5.38	$-5.88	$-5.59	$-1.41	$-1.59	$-5.41	$-4.63	$-5.01	$-1.37	$-3.26	$-4.99	$-5.26	$-5.29	$-1.16	$-1.03	$-0.94	$-0.85	$-0.78	$-0.66	$-0.58	$-0.43	$-0.34	$-0.57	$-0.50	$-0.44	$-0.49
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.82%	1.18%	1.13%	1.15%	1.62%	0.33%	1.26%	0.54%	1.22%	1.30%	1.13%	1.43%	0.15%	1.20%	1.32%	1.17%	1.02%

According to undefined Wall Street analysts, Cytokinetics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CYTK previous annual EPS of $NaN (undefined).

Cytokinetics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
XFOR	X4 Pharmaceuticals	$0.34	$3.67	979.41%	Buy
BDTX	Black Diamond Therapeutics	$2.43	$14.75	507.00%	Buy
INZY	Inozyme Pharma	$2.79	$14.67	425.81%	Buy
RLAY	Relay Therapeutics	$4.66	$19.40	316.31%	Buy
ARVN	Arvinas	$22.69	$71.00	212.91%	Buy
PLRX	Pliant Therapeutics	$12.73	$39.71	211.94%	Buy
ABOS	Acumen Pharmaceuticals	$2.37	$7.00	195.36%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
TERN	Terns Pharmaceuticals	$5.60	$14.25	154.46%	Buy
CYTK	Cytokinetics	$49.86	$83.23	66.93%	Buy
DYN	Dyne Therapeutics	$29.99	$43.88	46.32%	Buy
EWTX	Edgewise Therapeutics	$31.95	$45.00	40.85%	Buy
AMLX	Amylyx Pharmaceuticals	$5.23	$6.67	27.53%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
BPMC	Blueprint Medicines	$94.81	$109.71	15.72%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$57.07	$60.63	6.24%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy

CYTK Forecast FAQ

Is Cytokinetics a good buy?

Yes, according to 13 Wall Street analysts, Cytokinetics (CYTK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 84.62% of CYTK's total ratings.

What is CYTK's price target?

Cytokinetics (CYTK) average price target is $83.23 with a range of $45 to $120, implying a 66.93% from its last price of $49.86. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cytokinetics stock go up soon?

According to Wall Street analysts' prediction for CYTK stock, the company can go up by 66.93% (from the last price of $49.86 to the average price target of $83.23), up by 140.67% based on the highest stock price target, and down by -9.75% based on the lowest stock price target.

Can Cytokinetics stock reach $70?

CYTK's average twelve months analyst stock price target of $83.23 supports the claim that Cytokinetics can reach $70 in the near future.

What are Cytokinetics's analysts' financial forecasts?

Cytokinetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $22.56M (high $81.29M, low $1.15M), average EBITDA is $-22.563M (high $-1.15M, low $-81.295M), average net income is $-598M (high $-25.507M, low $-2.149B), average SG&A $129.66M (high $467.16M, low $6.61M), and average EPS is $-5.083 (high $-0.217, low $-18.262). CYTK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $252.04M (high $908.1M, low $12.85M), average EBITDA is $-252M (high $-12.85M, low $-908M), average net income is $-431M (high $100.67M, low $-1.888B), average SG&A $1.45B (high $5.22B, low $73.85M), and average EPS is $-3.66 (high $0.855, low $-16.045).

Did the CYTK's actual financial results beat the analysts' financial forecasts?

Based on Cytokinetics's last annual report (Dec 2023), the company's revenue was $7.53M, which missed the average analysts forecast of $35.61M by -78.85%. Apple's EBITDA was $-526M, beating the average prediction of $-98.573M by 433.86%. The company's net income was $-526M, beating the average estimation of $-408M by 28.93%. Apple's SG&A was $173.61M, missing the average forecast of $204.61M by -15.15%. Lastly, the company's EPS was $-5.45, beating the average prediction of $-4.04 by 34.90%. In terms of the last quarterly report (Sep 2023), Cytokinetics's revenue was $378K, missing the average analysts' forecast of $20.24M by -98.13%. The company's EBITDA was $-115M, beating the average prediction of $-20.241M by 470.26%. Cytokinetics's net income was $-129M, beating the average estimation of $-87.421M by 48.04%. The company's SG&A was $40.11M, missing the average forecast of $116.32M by -65.52%. Lastly, the company's EPS was $-1.35, beating the average prediction of $-0.743 by 81.73%